A5085055388- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Hormonal and reproductive studies
- Renal cell carcinoma treatment
- Medical Imaging Techniques and Applications
- Renal and related cancers
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Salivary Gland Tumors Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Ear and Head Tumors
- Cardiac Valve Diseases and Treatments
- Head and Neck Cancer Studies
- Bone health and treatments
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Heart rate and cardiovascular health
- Ion Channels and Receptors
- Cancer Genomics and Diagnostics
Royal Brisbane and Women's Hospital
2022-2024
Peter MacCallum Cancer Centre
2020-2023
The University of Melbourne
2020-2021
UNSW Sydney
2019
Prince of Wales Hospital
2019
Flinders Medical Centre
2011
To assess the activity and safety of sequential lutetium-177 (177 Lu)-PSMA-617 docetaxel vs on a background androgen deprivation therapy (ADT) in men with de novo metastatic hormone-naïve prostate cancer (mHNPC).UpFrontPSMA (NCT04343885) is an open-label, randomized, multicentre, phase 2 trial, recruiting 140 patients at 12 Australian centres. Key eligibility criteria include: histological diagnosis within weeks screening commencement; prostate-specific antigen (PSA) >10 ng/mL diagnosis; ≤4...
5017 Background: The VISION and TheraP trials have established the safety efficacy of 177 Lu-PSMA-617 in mCRPC with a 50% PSA response rate (PSA50-RR) 46% 66% median progression free survival (PFS) 8.7 5.1 months, respectively. More effective treatments are required as disease remains universal. Immunotherapy has limited single-agent mCRPC. We hypothesise that by potentially inducing immunogenic cell death, may act synergistically pembrolizumab, an anti-programmed death 1 inhibitor, to...
TPS271 Background: Combination immune checkpoint inhibitors (ICI) with ipilimumab and nivolumab has been shown to induce adaptive responses in patients mCRPC, albeit resulting modest clinical benefit. There is growing evidence that radiation may enhance the activity of ICI by modulating tumour microenvironment. We hypothesize radionuclide 177 Lu-PSMA-617 result immunogenic cell death therefore synergise combination improve long term outcomes. EVOLUTION aims determine safety mCRPC. Methods:...
Prostate-specific membrane antigen (PSMA) PET/CT is a novel imaging technique for the detection and staging of either primary or recurrent prostate cancer. Early studies demonstrated its improved sensitivity specificity over in combination with other currently employed techniques, such as multiparametric MRI, bone scan, PET CT. However, lack strength confidence these has meant incorporation PSMA into clinical guidelines practice been limited to date. In response, number high-quality...
Abstract Purpose There is an emerging role of the use Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in renal cell carcinoma. Herein, we report our experience PSMA PET recurrent or metastatic carcinoma (RCC). Methods A retrospective analysis all patients who underwent for suspected de-novo RCC between 2015 and 2020 at three institutions was performed. The primary outcome change management (intensification de-intensification) following scan. Secondary outcomes...
TPS180 Background: 177 Lu‐PSMA-617 (Lu-PSMA) is a radiolabeled small-molecule that binds with high affinity to PSMA enabling highly targeted delivery of beta radiation prostate cancer cells. In metastatic castration-resistant cancer, Lu-PSMA showed superior activity Cabazitaxel in the TheraP trial. Although androgen deprivation therapy (ADT) + Docetaxel standard care for de novo high-volume mHNPC, outcomes remain sub-optimal many patients. We hypothesize prior docetaxel will achieve higher...
Abstract We report a case of 75-year-old man with concomitant metastatic prostate cancer and progressive follicular lymphoma the utility molecular imaging in differentiating these 2 conditions. 18 F-FDG PET/CT can offer accurate staging many cancers, although its role is limited. The F-DCFPyL (PSMA) evolving has been demonstrated to have higher sensitivity than conventional bone scan CT scan. Together, FDG PSMA studies may noninvasive approach individually characterize malignancies, aiding...
Summary Adenoid cystic carcinoma is a rare disease and characterised by slow but unrelenting local progression risk of haematogenous metastases. We present case locally unresectable where PSMA PET/CT provided complementary staging early treatment response assessment.
Background/Objectives: Prostate-specific membrane antigen (PSMA) PET/CT is more accurate than CT and bone scans for staging intermediate high-risk prostate cancer (PCa). Fluorodeoxyglucose (FDG) PET has improved disease characterisation in metastatic castrate-resistant PCa (mCRPCa) indicates patients with a particularly poor prognosis. The aim of this study was to assess the benefits both PSMA FDG by direct intra-individual comparison uptake patterns. Methods: Patients who underwent from...
TPS264 Background: High-risk localised prostate cancer (HRCaP) is treated by radical prostatectomy (RP) or radiotherapy. Despite curative intent, a significant number of men will progress with metastatic disease local recurrence. Lutetium-177 radiolabelled to the small molecule PSMA-617 targeting prostate-specific membrane antigen (Lu-PSMA) has proven efficacious in castration-resistant who have progressed after standard-of-care. The LuTectomy trial evaluates whether administration Lu-PSMA...
4540 Background: There is emerging role of the use PSMA PET in RCC. Herein, we report our experience recurrent or metastatic RCC Brisbane, Australia. Methods: Patients (pts) who underwent and conventional diagnostic CT for between 2015 2020 at three institutions were identified. Retrospective chart reviews conducted using standardized collection template. The outcomes included percentage patients had a change management secondary to findings, comparison metastasis detection vs. CT, biopsy...